New antibody cocktail targets stubborn liver disease after stem cell transplants

NCT ID NCT06364319

Not yet recruiting Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a lab-made antibody called anti-CD25 rhMAb for people with chronic graft-versus-host disease (cGVHD) of the liver that hasn't improved with steroids. The antibody is given alongside standard immune-suppressing drugs. The trial will include 30 adults aged 16-65 who have had a stem cell transplant. The goal is to see if this combination can shrink liver damage and control the disease better than current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-CD25 rhMAb (a lab-made antibody) combined with prednisone, ruxolitinib, and cyclosporine
What this could lead to: If it works, this could offer a new treatment option for people with severe liver graft-versus-host disease that hasn't responded to steroids.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The treatment also requires ongoing immune-suppressing drugs, which carry risks of infection and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CGVHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CGVHD

More trials for these conditions

Other studies related to the condition(s) this trial covers.